medigraphic.com
ISSN 1405-8871 (Print)

2024, Number 2

<< Back Next >>

Aten Fam 2024; 31 (2)

Therapeutic Adherence in Type 2 Diabetes Patients Treated with Metformin and Sitagliptin

Ramos-Mejía AK, Alvarado-Gutiérrez T

Language: Spanish
References: 23
Page: 115-120
PDF size: 205.90 Kb.


ABSTRACT

Objective: to estimate therapeutic adherence in patients with type 2 diabetes who have initiated combination therapy based on sitagliptin with metformin. Methods: an analytical cross-sectional study where the sample size consisted of 320 patients, obtained using the formula for finite proportions by non-randomized sampling by quotas. During the period from March to September 2022, therapeutic adherence was evaluated in patients who initiated sitagliptin therapy with metformin using the MMAS-8 scale. Descriptive statistics were used to analyze qualitative variables, such as frequencies and percentages, and quantitative variables were measured for central tendency and dispersion. Inferential statistics were analyzed using χ2. Results: 55.6% of the patients had average therapeutic adherence. The analysis found no statistically significant association between gender and therapeutic adherence (p= 0.796). Most participants with basic education had medium therapeutic adherence, and there were no significant differences between the levels of schooling (p= 0.89). Comorbidities were present in 80.9% of the participants, with a predominance of medium therapeutic adherence, but no significant association was found (p= 0.620). Conclusion: the therapeutic adherence was only moderate. Improving adherence is a significant challenge for healthcare professionals, and further research should be conducted to optimize the management of chronic diseases.


REFERENCES

  1. INEGI. Características de las defunciones registradasen México durante enero a agosto de 2020[Internet]. [citado 2021 Jun 15]. Disponible en:https://www.inegi.org.mx/contenidos/saladeprensa/boletines/2021/EstSociodemo/DefunDefuncionesRegist2020_Pnles.pdf

  2. Organización Mundial de la Salud. Diabetes [Internet].[Citado 2021 Jun 15]. Disponible en:https://www.who.int/es/news-room/fact-sheets/detail/diabetes

  3. Basto-Abreu A, López-Olmedo N, Rojas-MartínezR, Aguilar-Salinas CA, Moreno-Banda GL, CarnallaM, et al. Prevalencia de prediabetes y diabetesen México: Ensanut 2022. Salud Publica Mex.2023;65(Supl I):S163–8.

  4. Ortega CJJ, Sánchez HD, Rodríguez MOA, OrtegaLJM. Adherencia terapéutica: un problemade atención médica. Acta Méd Grupo Ángeles.2018;16(3):226–232.

  5. OMS. Adherencia a los tratamientos a largo plazo:pruebas para la acción. [Internet]. [Citado 2021Sep 10] Disponible en: https://www.paho.org/hq/dmdocuments/2012/WHO-Adherence-Long-Term-Therapies-Spa-2003.pdf

  6. Cutler RL, Fernandez-Llimos F, Frommer M, BenrimojC, Garcia-Cardenas V. Economic impact ofmedication non-adherence by disease groups: a systematicreview. BMJ Open. 2018;8(1):e016982.

  7. Pagès-Puigdemont N, Valverde-Merino MI. Métodospara medir la adherencia terapéutica. ArsPharm. 2018;59(3):163–172.

  8. Pascacio-Vera G. D, Ascencio-Zarazua G. E,Cruz-León A, Guzmán-Priego C. G. Adherenciaal tratamiento y conocimiento de la enfermedaden pacientes con diabetes mellitus tipo 2. Salud enTabasco. 2016;(22,1-2):23–31.

  9. Vargas Sánchez CG, Toledo Hernández A. Adherenciaal tratamiento y su relación con el controlmetabólico en pacientes con diabetes mellitustipo 2, en una unidad de medicina familiaren Cuernavaca, Morelos, México. Aten Fam.2018;25(4):146-150.

  10. Benítez-Agudelo JC, Barceló-Martínez E, Gelves-Ospina M, Díaz-Bernier A, Orozco-Acosta E. Influenciade las variables neuropsicológicas y psicológicasen la adherencia al tratamiento en la DM2.Rev Mex Neuroci. 2017;18(2):39-50.

  11. Long H, Bartlett YK, Farmer AJ, French DP. Identifyingbrief message content for interventions deliveredvia mobile devices to improve medicationadherence in people with type 2 diabetes mellitus:A rapid systematic review. J Med Internet Res.2019;21(1):e10421.

  12. Fitzpatrick C, Gillies C, Seidu S, Kar D, IoannidouE, Davies MJ, et al. Effect of pragmatic versusexplanatory interventions on medication adherencein people with cardiometabolic conditions: asystematic review and meta-analysis. BMJ Open.202;10(7):e036575.

  13. Liu D, Jin B, Chen W, Yun P. Dipeptidyl peptidase4 (DPP-4) inhibitors and cardiovascular outcomesin patients with type 2 diabetes mellitus (T2DM):a systematic review and meta-analysis. BMC PharmacolToxicol. 2019;20(1):15.

  14. Dilla T, Valladares A, Lizán L, Sacristán JA. Adherenciay persistencia terapéutica: causas, consecuenciasy estrategias de mejora. Aten Primaria.2009;41(6):342–348.

  15. Moon SJ, Lee WY, Hwang JS, Hong YP, MoriskyDE. Accuracy of a screening tool for medicationadherence: A systematic review and meta-analysisof the Morisky Medication Adherence Scale-8.PLoS One. 2017;12(11):e0187139.

  16. Martinez-Perez P, Orozco-Beltrán D, Pomares-Gomez F, Hernández-Rizo JL, Borras-Gallen A,Gil-Guillen VF, et al. Validation and psychometricproperties of the 8-item Morisky Medication AdherenceScale (MMAS-8) in type 2 diabetes patientsin Spain. Aten Primaria. 2021;53(2):101942.

  17. Náfrádi L, Nakamoto K, Schulz PJ. Is patientempowerment the key to promote adherence? Asystematic review of the relationship between selfefficacy,health locus of control and medicationadherence. PLoS One. 2017;12(10):e0186458.

  18. Shams N, Amjad S, Kumar N, Ahmed W, SaleemF. Drug non-adherence in type 2 diabetes mellitus;Predictors and associations. J Ayub Med Coll Abbottabad.2016;28(2):302-307.

  19. McGovern A, Tippu Z, Hinton W, Munro N,Whyte M, de Lusignan S. Comparison of medicationadherence and persistence in type 2 diabetes:A systematic review and meta-analysis. DiabetesObes Metab. 2018;20(4):1040–1043.

  20. Lautsch D, Alsumali A, McLeod E, Kuang Y, HeJ, Singh R, et al. Comparative Efficacy of Dualand Single Initiation of Add-On Oral AntihyperglycemicAgents in Type 2 Diabetes Uncontrolledon Metformin Alone: A Systematic Literature Reviewand Network Meta-Analysis. Diabetes Ther.2021;12(1):389–418.

  21. Jannoo Z, Mamode Khan N. Medication adherenceand diabetes self-care activities among patientswith type 2 diabetes mellitus. Value Health RegIssues. 2019;18:30-5.

  22. Bakar ZA, Fahrni ML, Khan TM. Patient satisfactionand medication adherence assessmentamongst patients at the diabetes medication therapyadherence clinic. Diabetes Metab Syndr.2016;10(2 Suppl 1):S139–43.

  23. Al-Haj Mohd MMM, Phung H, Sun J, MoriskyDE. Improving adherence to medication in adultswith diabetes in the United Arab Emirates. BMCPublic Health. 2016;16(1):857.




2020     |     www.medigraphic.com